CoChat

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Reply to Alffenaar et al

Peloquin, Charles A., Dorman, Susan E., Vernon, Andrew, Battista Migliori, Giovanni, Nahid, Payam · 2017 · Clinical Infectious Diseases

Abstract

To the Editor—We thank Alffenaar and colleagues for their thoughtful review of the therapeutic drug monitoring (TDM) portion of the newly released tuberculosis treatment guidelines [1–3]. We agree that there are strong data to support concentration-response relationships for many tuberculosis drugs, ranging from in vitro data to animal model data to clinical trial data [4–6]. Furthermore, we agree that for most tuberculosis drugs, this concentration response currently is best described by the relationship between the free drug (not protein bound) area under the concentration-time curve divided by the minimum inhibitory concentration [7, 8]. This is described in greater detail in Appendix C to the new guidelines, and readers are encouraged to review this document (http://cid.oxfordjournals.org/content/suppl/2016/07/20/ciw376.DC1/ciw376supp_file3.pdf). Recent studies on high-dose rifampin and high-dose rifapentine not only demonstrate that these drug exposure-response relationships exist in patients with tuberculosis, but suggest that controlling these exposures could improve treatment outcomes [6, 9]. Many clinical factors affect treatment outcome (eg, extent of disease, cavitation, individual metabolism, adherence, frequency of dosing, comorbid disease); unlike many of these factors, drug exposure can be directly influenced by the clinician. There is wide variety in the application of TDM across US, Canadian, and European tuberculosis centers, ranging from very frequent usage to virtually no usage. These differences reflect varying opinions about the costs and benefits of TDM, and the level of proof needed to adopt the technology routinely. Such differences in opinion existed among the authors of the new tuberculosis treatment guidelines; hence, the guidelines reflect a compromise [1]. Alffenaar and colleagues correctly point out that a prospective, randomized study of TDM could be highly informative, but we agree that it would incur considerable expense in the context of already constrained tuberculosis research and tuberculosis program budgets. Thankfully, many clinicians in the United States, Canada, and Europe have begun publishing their experiences with TDM, and at a minimum, the data show that one can control drug exposure [7, 8, 10]. The debate continues about what optimal exposures might be. Alffenaar and colleagues further point out the potential utility of dried blood spot (DBS) technology to eliminate the freezing requirement for samples, easing the collection and shipping challenges. This would be particularly advantageous in high-burden countries with limited access to freezers and dry ice for shipping. Some drugs (eg, isoniazid, ethionamide, and cycloserine) are less stable than others (eg, rifamycins [moderate stability], pyrazinamide, or fluoroquinolones [high stability]). Thus, DBS technology also has limitations. Discussion continues on the cost efficiency of these different approaches (serum/plasma vs DBS). Greater utilization will likely depend on greater success in lowering costs for shipping and assay. TDM is one important tool that can be used to optimize drug exposure, and thus to increase efficacy or potentially to shorten treatment duration. Shorter durations could produce cost savings that more than offset assay costs. Additional research on this topic is encouraged. Potential conflicts of interest. C. A. P. has received research support from Jacobus Pharmaceuticals. He is the Director of the Infectious Disease Pharmacokinetics Lab at the University of Florida, but this clinical laboratory does not pay any of his salary. A. V. has served as the chief of a Centers for Disease Control and Prevention (CDC) clinical research branch doing clinical trials in tuberculosis, which receives institutional support through pharmaceutical company support to the CDC Foundation. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Overview

Integrity signals

Registry

Crossref · 10.1093/cid/ciw679

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 10 references

Cited by

Metadata

Authors
Peloquin, C. A., Dorman, S. E., Vernon, A., Battista Migliori, G., & Nahid, P.
Affiliations
  • University of Florida (US)
  • Johns Hopkins University (US)
  • Centers for Disease Control and Prevention (US)
  • University of California, San Francisco (US)
Corresponding author
Peloquin, Charles A.
Venue
Clinical Infectious Diseases
Published
2016-10-26
Volume
64
Issue
1
Pages
105-106
ISSN
  • 1058-4838 (ISSN-L)
  • 1537-6591
OpenAlex
W2545757685
Cited by
6
References
10
Citations by year
2019: 2 · 2018: 1 · 2017: 3
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Infectious Diseases (publishedVersion)
  • PubMed (publishedVersion)
  • HighWire Press Open Archive (submittedVersion)
Funders
National Institutes of Health (CC999999)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
  • Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
Keywords
therapeutic drug monitoring, tuberculosis treatment guidelines, concentration-dependent effects, minimum inhibitory concentration, rifampicin, rifapentine, dried blood spots, isoniazid, ethionamide, cycloserine, drug stability, high-burden countries
MeSH terms
Centers for Disease Control and Prevention, U.S., Communicable Diseases, Disease Susceptibility, Humans, Tuberculosis, United States

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.